Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours - Full Text View

Sponsor:	Ipsen
Information provided by:	Ipsen
ClinicalTrials.gov Identifier:	NCT00353496

Purpose

The study will compare the difference between lanreotide Autogel and placebo on progression free survival in patients who have an endocrine tumour in the pancreas or intestines.

Condition	Intervention	Phase
Endocrine Tumors	Drug: lanreotide (Autogel formulation) Other: Placebo	Phase III

Study Type:	Interventional
Study Design:	Treatment, Randomized, Double Blind (Subject, Investigator), Placebo Control, Parallel Assignment, Efficacy Study
Official Title:	Phase III, Randomised, Double-blind, Stratified Comparative, Placebo Controlled, Parallel Group, Multi-centre Study to Assess the Effect of Deep Subcutaneous Injections of Lanreotide Autogel 120mg Administered Every 28 Days on Tumour Progression Free Survival in Patients With Non-functioning Entero-pancreatic Endocrine Tumour

Resource links provided by NLM:

MedlinePlus related topics: Cancer

Drug Information available for: Lanreotide acetate

U.S. FDA Resources

Further study details as provided by Ipsen:

Primary Outcome Measures:

Time to either disease progression or death [ Time Frame: Within 96 weeks after the first study drug administration ] [ Designated as safety issue: No ]

Secondary Outcome Measures:

Proportion of patients alive & without progression [ Time Frame: Week 48 & 96 ] [ Designated as safety issue: No ]
Side effects [ Time Frame: For the duration of the study ] [ Designated as safety issue: Yes ]
Pharmacokinetic profile of lanreotide [ Time Frame: Week 1,4, 12, 20, 24, 36, 48, 72, 96 ] [ Designated as safety issue: No ]
Quality of life [ Time Frame: At every visit (excluding screening) ] [ Designated as safety issue: No ]
Tumour markers [ Time Frame: At every visit (excluding screening) ] [ Designated as safety issue: No ]

Estimated Enrollment:	200
Study Start Date:	June 2006
Estimated Study Completion Date:	June 2012
Estimated Primary Completion Date:	June 2012 (Final data collection date for primary outcome measure)

Arms	Assigned Interventions
1: Experimental	Drug: lanreotide (Autogel formulation) 120mg administered via deep subcutaneous injection every 28 days for a maximum period of 2 years.
2: Placebo Comparator	Other: Placebo Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 2 years.

Eligibility

Ages Eligible for Study:	18 Years and older
Genders Eligible for Study:	Both
Accepts Healthy Volunteers:	No

Criteria

Inclusion Criteria:

Endocrine tumour in the intestine or pancreas and with locally advanced or metastatic disease
No hormone related symptoms
Well or moderately differentiated tumour confirmed by histology
Tumour lesions which are measurable by a CT or MRI scan

Exclusion Criteria:

Previously treated with a somatostatin analogue unless more than 6 months ago and given for no more than 15 days
Treated within the last 6 months with interferon, chemoembolisation or chemotherapy or at any time with a radionuclide
Had a previous cancer except basal cell carcinoma and/or in situ carcinoma of the cervix/uterus and/or patients treated with curative intent and free from disease for 5 years
Pregnant or lactating
Females must use adequate contraception during the study

Contacts and Locations

Please refer to this study by its ClinicalTrials.gov identifier: NCT00353496

Contacts

Contact: Ipsen Recruitment Enquiries

clinical.trials@ipsen.com

Show 66 Study Locations

Sponsors and Collaborators

Ipsen

Investigators

Study Director:

Joelle Blumberg, MD

Ipsen

More Information

No publications provided

Responsible Party:	Ipsen ( Joelle Blumberg )
Study ID Numbers:	2-55-52030-726
Study First Received:	July 17, 2006
Last Updated:	August 27, 2009
ClinicalTrials.gov Identifier:	NCT00353496 History of Changes
Health Authority:	United States: Food and Drug Administration; United Kingdom: Medicines and Healthcare Products Regulatory Agency; France: Ministry of Health; Netherlands: The Central Committee on Research Involving Human Subjects (CCMO); Belgium: The Federal Public Service (FPS) Health, Food Chain Safety and Environment; Belgium: Directorate general for the protection of Public health: Medicines; Spain: Spanish Agency of Medicines; Germany: Federal Institute for Drugs and Medical Devices; Poland: Ministry of Health; Greece: Ministry of Health and Welfare; Czech Republic: State Institute for Drug Control; Denmark: Danish Medicines Agency; Sweden: Medical Products Agency; Italy: Ministry of Health; Austria: Federal Ministry for Health Family and Youth

Keywords provided by Ipsen:

Non functioning entero-pancreatic tumours

Additional relevant MeSH terms:

Neoplasms by Histologic Type
Digestive System Neoplasms
Antineoplastic Agents
Pancreatic Neoplasms
Angiopeptin
Endocrine System Diseases
Adenoma, Islet Cell
Cardiovascular Agents
Pharmacologic Actions

Neoplasms
Lanreotide
Neoplasms by Site
Digestive System Diseases
Therapeutic Uses
Pancreatic Diseases
Adenoma
Endocrine Gland Neoplasms
Neoplasms, Glandular and Epithelial

ClinicalTrials.gov processed this record on November 27, 2009